The Blueprint Was Never Built for You: What Women Were Never Told About Their Biology
If you have ever sat in a doctor's office holding a lab report that says everything looks normal, while every part of you knows something is off, I want you to hear this clearly. You are not imagining what you are feeling or being overly sensitive. And you are not the exception. You are a woman being measured against a system that was not built with your biology in mind, and the disconnect you feel between what the paperwork says and what your body is telling you is one of the most consistent patterns I have seen in nearly three decades of working in functional and integrative health.
Here is what most women were never told. For most of modern medical history, research was conducted on male bodies, and the findings were applied to women as if the biology were interchangeable. Women were formally excluded from most clinical trials in the United States until 1993, and even now, the sex-specific analysis of research findings remains inconsistent. The diagnostic ranges you are measured against, the medication doses you are prescribed, the definition of what counts as normal- all of it was largely shaped by data that did not include you. That is not a small footnote in the history of medicine. That is the foundation of the care women receive today.
Once you understand that, so much of what you have been carrying begins to make sense. The fatigue that does not resolve with sleep. The labs that come back fine while your life slowly gets harder to run. The sense that you are advocating for something you cannot quite name yet. There is a real reason for that, and it deserves a closer look. In the words that follow, I want to walk you through how this gap came to exist, where it still shapes the care you are receiving right now, and what becomes possible when you begin to see your own biology through a lens that was designed for it.
Why Women's Health Research Still Lags Behind
To understand why women's health research still lags behind, you have to look at the logic that shaped medicine in the first place. For most of the last century, the male body was treated as the default reference standard for human physiology. Researchers built studies, established clinical norms, and set the parameters of what a healthy body looked like based on data drawn almost entirely from men. The assumption underneath was that if you understood how disease and treatment worked in a male body, you understood how they worked in every body, and any variation in a woman could be adjusted for later. That assumption became the operating system of modern medicine, and it is still shaping the care we receive today, in appointments happening this week.
Female physiology was viewed through that same lens, not as a distinct system worth studying on its own terms, but as a complication of the male model. Hormonal cycling, reproductive potential, and sex-based metabolic differences were treated as confounding variables that made data harder to interpret, so women were excluded from clinical trials to keep the research cleaner. What that produced, over decades, was a body of health research that did not account for the very biology it was eventually going to be applied to. Even now, sex-specific analysis of trial data remains inconsistent, which means we are still generating findings that do not always tell us how a woman will respond, only how the average participant did.
This is why the gap persists. The foundation itself was built on data that left us out, and rebuilding a foundation takes time, funding, and a real shift in what the field considers worth studying.
What Changed After 1993
Once inclusion was mandated, the landscape did begin to shift. The NIH established the Office of Research on Women's Health, clinical trials were finally required to enroll women in meaningful numbers, and sex was formally recognized as a variable worth analyzing rather than a complication worth excluding. Over the following decades, more studies included women, and dedicated funding streams for women's health research began to grow. That progress is real, and it matters. What is also true is that representation on paper has not fully translated into representation in practice. Enrollment numbers improved, but the analysis of how findings differ between women and men has remained inconsistent, which means much of the data being generated is still not being read through a sex-specific lens. The women it was meant to serve are still often left out.
How the Research Gap Still Shows Up in Women's Care Today
The consequences of that history are not academic. They are living in the day-to-day care women are receiving right now, in the appointments they are walking into this week. Even with inclusion mandates in place, women still make up a minority of participants in clinical trials for many of the conditions that affect us most. Cardiovascular disease is the leading cause of death for women in the United States, and yet women remain underrepresented in that clinical trial data relative to how many of us are living with the disease. The same pattern shows up in trials for psychiatric conditions, autoimmune disease, and pain research, areas where women are being diagnosed at higher rates than men and the data is still not fully reflecting us.
Even when women are included, sex-specific results are inconsistently reported. Studies often pool the data, publish an average outcome, and never look at whether the findings actually differ by biological sex. That means a medication may work beautifully on average and respond very differently in a female body, and the difference will not be captured anywhere in the published research. This is one of the reasons the FDA has withdrawn medications from the market for safety concerns that affected women at a disproportionately higher rate than men. The signal was there in our biology. It was not there in the data.
These patterns quietly reinforce each other. Underrepresentation in trials produces incomplete data. Incomplete data produces clinical guidelines that do not account for sex differences. Guidelines built on that foundation shape the health outcomes women experience, the answers we receive in appointments, and the treatments we are offered. In my own practice, I sit with women every week whose symptoms were minimized or misread because the diagnostic frameworks used to evaluate them were never built with female physiology as the reference point. It is a system that keeps returning us to the same starting point, and it is why the frustration you may be carrying about your own care is not personal. It is structural, and it is well-earned.
Wondering if your stress, fatigue, and overwhelm are signs that your body is carrying more than it should? Take the free quiz to uncover the hidden patterns affecting your energy, resilience, and recovery.
Discover What May Be Draining Your EnergyWhere the Gap Is Most Visible: Heart Disease
If there is one place the research gap becomes impossible to ignore, it is here. For years, what we understood about heart disease was drawn almost entirely from how it shows up in men. The crushing chest pain. The pain radiating down the left arm. That became the picture every physician was trained to recognize, and it is still the picture most women carry in their minds when they think about what a heart attack looks like. But a woman's heart often speaks in a different language. It shows up as a wave of fatigue that does not match anything she did that day. A shortness of breath climbing the stairs she climbs every morning. A heaviness between her shoulder blades and jaw pain she cannot explain. Some women even experience nausea that feels vaguely like the flu.
Because those signals did not match the male template, women have been sent home from emergency rooms with explanations that their symptoms are caused by anxiety, indigestion, or stress, while something far more serious was unfolding inside them. Heart disease is still the leading cause of death for women in this country, and much of that heartbreaking gap traces back to how long the clinical picture was drawn from only half the population. Your body has always been telling the truth. The framework simply was not built to hear it.
What This Means for How You Approach Your Own Health
Once you understand how much of standard medical reference data was built without female physiology as the baseline, a real shift begins to happen in how you think about your own health. The population averages you are being measured against were not built around you. That does not mean the data is useless. It means it is incomplete, and incomplete data can only take you so far when the question is what is going on inside your body.
A more complete picture tends to come from an approach that treats you as an individual case rather than assuming you fit a generalized standard. This is where functional health becomes useful as a lens. Instead of relying solely on population-level reference ranges, functional health looks at how your hormones, stress physiology, recovery capacity, and inflammation are interacting for you specifically. It asks what your body is doing right now, not what an average body did in a study you were never part of. It considers the patterns across your systems, not just the isolated markers on a single lab report.
This is the starting point of the work I do with the women I work with. Before we look at any protocol, we look at the gap itself. We acknowledge that many of the frameworks used to evaluate a woman were not designed to see her clearly, and we build from there. Symptoms that do not fit a standard model are not dismissed as anxiety or aging or stress. They are treated as data.
None of this is a promise of a shortcut. It is simply a more honest lens. When the reference point finally accounts for the body being evaluated, the whole picture of your health, your care, and your research into your own patterns begins to make far more sense.
FAQs
-
The women's health research gap refers to the long-standing shortfall in medical research that was conducted on, analyzed for, and applied to female bodies. For most of modern medicine, clinical trials studied primarily male participants, and the findings were used to shape care for everyone. The gap describes what was missed, misread, or never studied in women as a result, and how that absence still shapes the standards used to evaluate our health today.
-
In 1977, following the thalidomide tragedy, which caused severe birth defects in children whose mothers had taken the drug during pregnancy, the FDA issued a policy to exclude women of reproductive potential from early-phase clinical trials. The intent was protective, but the guidance was applied so broadly that most women of childbearing age were left out of research entirely for more than a decade, whether or not pregnancy was ever a factor.
-
It has, and there is still real ground to cover. Since the 1993 NIH Revitalization Act, women have been included in clinical research in far greater numbers, and dedicated funding for women's studies has grown. Yet meaningful gaps remain in how trials are designed, whether sex-specific data is actually analyzed and published, and how consistently funding reflects the conditions that affect women most.
-
The gap shows up in the exam room. Women often face diagnostic delays, dosing that was calibrated on male bodies, and symptoms that get attributed to stress, anxiety, or aging rather than investigated further. That pattern shapes the care women receive and the health outcomes that follow, and it is one of the reasons a woman can be told her labs look fine while her body is telling her something entirely different, including in serious conditions like heart disease.
Final Thoughts
If there is one thing I want you to take from all of this, it is that what you have been experiencing in your body, in your labs, and in your appointments is not a personal failure. It is not you being too sensitive, too anxious, or too much. It is the predictable, human consequence of a research gap that has been decades, and in truth centuries, in the making. Every woman who has ever left an appointment feeling unseen is standing on the other side of a system that was not built to see her clearly in the first place.
Understanding that changes something. It moves the question from what is wrong with me to what has this framework been missing about me. That single shift is where real self-advocacy begins, and it is where the possibility of a different kind of health story begins to open up.
If any of this resonates, HealthStyle by Dr. Kenna is where this kind of work lives. We use a functional health lens to look at the patterns standard care may be built to miss, and to see you as the individual you are. No urgency or promises. Only an invitation to be seen more fully. Your body has always been telling the truth. You deserve a lens that can finally hear it.
Doing all the right things but still feeling tired, wired, or not quite like yourself? Functional health coaching connects the signals you've been managing on your own into a strategy built for your actual life.
Explore Functional Health CoachingResearch & Sources
A New Vision for Women's Health Research: Transformative Change at the National Institutes of Health. National Academies of Sciences, Engineering, and Medicine (2024). A congressionally mandated report finding that only 8.8 percent of NIH research spending from fiscal years 2013 to 2023 targeted women's health research, and that women spend on average 9 years in poor health, 25 percent more time than men. https://www.ncbi.nlm.nih.gov/books/NBK612405/
Participation of Women in Cardiovascular Trials From 2017 to 2023: A Systematic Review. JAMA Network Open (2025). Systematic review of 1,079 cardiovascular clinical trials registered from 2017 to 2023, showing significantly lower female-to-male ratios in trials on arrhythmia, coronary heart disease, acute coronary syndrome, and heart failure. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12400126/
Women Are Still Underrepresented in Clinical Trials for Cardiovascular Disease Drugs. American Journal of Managed Care (2025). Analysis of trials supporting 36 cardiovascular drug approvals found that of 224,417 participants, only 34 percent were women, despite cardiovascular disease being the leading cause of death among women. https://www.ajmc.com/view/women-are-still-underrepresented-in-clinical-trials-for-cardiovascular-disease-drugs
Drug Safety: Most Drugs Withdrawn in Recent Years Had Greater Health Risks for Women. U.S. Government Accountability Office (2001). Foundational federal report finding that 8 of the 10 prescription drugs withdrawn from the U.S. market between January 1997 and December 2000 posed greater health risks for women than for men. https://www.gao.gov/products/gao-01-286r
The Under-Representation of Women in Cardiovascular Clinical Trials: State-of-the-Art Review and Ethical Considerations. American Heart Journal (2024). Comprehensive review documenting the ongoing under-representation of women in cardiovascular trials investigating drugs, acute coronary syndrome, heart failure, and interventional devices, referencing the FDA's 2024 Diversity Action Plans as a call for change. https://www.sciencedirect.com/science/article/pii/S0002870324003405
Disclaimer
This content is based on nearly three decades of clinical experience and is provided for educational and informational purposes only. The insights and perspectives shared here reflect a functional health approach rooted in evidence, and are not intended to diagnose, treat, cure, or prevent any condition, nor to replace personalized guidance from your own qualified healthcare provider.
Every woman's physiology, history, and circumstances are different, and what applies in one situation may not apply in another. If you are experiencing persistent or concerning symptoms, please consult a licensed professional who can evaluate your individual needs.
